论文部分内容阅读
目的探讨阿托伐他汀联合依折麦布对冠心病(CHD)患者血脂指标、血清C反应蛋白(CRP)水平的影响。方法选取江苏省灌云县人民医院2013年5月至2015年1月收治的100例确诊CHD患者,根据入院顺序分为单用组和联合组各50例,两组患者入院后均给予冠心病常规治疗方案+阿托伐他汀(单用组),联合组加用依折麦布治疗,两组患者连续用药4周。结果治疗后两组患者的总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)水平较治疗前显著的降低,高密度脂蛋白胆固醇(HDL-C)水平较治疗前显著的升高且差异均具有统计学意义(P<0.05);治疗后联合组患者的TC、TG、LDL-C水平显著低于单用组、HDL-C水平显著高于单用组,差异均具有统计学意义(P<0.05)。治疗后联合组患者的TC达标率(78%)、LDL-C达标率(76%)高于单用组(P<0.05)。治疗后联合组和单用组的CRP在第2周、第4周均较治疗前显著的降低(P<0.05),联合组降低更加显著(P<0.05)。结论阿托伐他汀联合依折麦布能够更显著的改善CHD患者血脂指标、血清C反应蛋白水平。
Objective To investigate the effects of atorvastatin combined with ezetimibe on serum lipids and serum C-reactive protein (CRP) in patients with coronary heart disease (CHD). Methods 100 cases of CHD diagnosed in People’s Hospital of Guanyun County, Jiangsu Province from May 2013 to January 2015 were enrolled. According to the sequence of admission, they were divided into single group and combined group of 50 cases. Both groups were given coronary heart disease Conventional treatment regimen + atorvastatin (single use group), combined with ezetimibe treatment, two groups of patients for 4 weeks of continuous medication. Results After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in both groups were significantly lower than those before treatment and the levels of high-density lipoprotein cholesterol The levels of TC, TG and LDL-C in the combined group were significantly lower than those in the single treatment group after treatment, and the levels of HDL-C in the combined group were significantly higher than those in the single treatment group (P <0.05) , The differences were statistically significant (P <0.05). After treatment, the TC compliance rate (78%) and LDL-C compliance rate (76%) were higher in the combination group than in the control group (P <0.05). After treatment, the CRP in the combination group and the single use group were significantly lower than those before treatment in the second week and the fourth week (P <0.05), and the combination group decreased more significantly (P <0.05). Conclusions Atorvastatin combined with ezetimibe can significantly improve the level of serum lipids and serum C - reactive protein in CHD patients.